A Single Dose Escalation Study of PCSK9 Inhibitor (JS002) in Health Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 11, 2017

Primary Completion Date

August 14, 2018

Study Completion Date

August 14, 2018

Conditions

Hypercholesterolemia

Interventions

DRUG

JS002

JS002, Subcutaneous or intravenous injection of a single dose of JS002, dose cohort according to ascending dose design

DRUG

Placebo

Placebo,Subcutaneous or intravenous injection of a single dose of placebo, dose cohort according to ascending dose design

Trial Locations (1)

Fuwai Hospital Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors

lead

Shanghai Junshi Bioscience Co., Ltd.

OTHER

NCT04197817 - A Single Dose Escalation Study of PCSK9 Inhibitor (JS002) in Health Subjects | Biotech Hunter | Biotech Hunter